DeepMed Research

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety Study of Hepatitis E Vaccine (HEV239)

Phase 1

Completed

Conditions: Hepatitis E
Immunisation

Interventions: Biological: HEV 239
Other: Placebo

First Posted Date: 2019-02-01

Last Posted Date: 2021-09-24

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 25

Registration Number: NCT03827395

Locations: 🇺🇸
Emory Children's Center - Pediatric Infectious Diseases, Atlanta, Georgia, United States

Retrospective Chart Review of Candida Fungemia

Completed

Conditions: Candida Fungemia

First Posted Date: 2019-02-01

Last Posted Date: 2020-11-27

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 75

Registration Number: NCT03827330

Locations: 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States

Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals

Phase 1

Completed

Conditions: Influenza

Interventions: Biological: H5N1 pISV

First Posted Date: 2019-01-25

Last Posted Date: 2022-02-16

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 32

Registration Number: NCT03816878

Locations: 🇺🇸
Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States

Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults

Phase 1

Completed

Conditions: Influenza Infection

Interventions: Biological: VRC-FLUNPF099-00-VP (H1ssF_3928)

First Posted Date: 2019-01-24

Last Posted Date: 2022-04-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 52

Registration Number: NCT03814720

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART

Phase 1

Terminated

Conditions: HIV Infections

Interventions: Biological: Placebo
Biological: Cemiplimab

First Posted Date: 2018-12-26

Last Posted Date: 2022-03-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 5

Registration Number: NCT03787095

Locations: 🇺🇸
Chapel Hill CRS, Chapel Hill, North Carolina, United States
🇺🇸
Alabama CRS, Birmingham, Alabama, United States
🇺🇸
UCSD Antiviral Research Center CRS, San Diego, California, United States

Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults

Phase 1

Completed

Conditions: Human Immunodeficiency Virus Prevention
Human Immunodeficiency Virus (HIV)

Interventions: Biological: VRC-HIVRGP096-00-VP
Other: Alum Adjuvant

First Posted Date: 2018-12-20

Last Posted Date: 2021-08-12

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 16

Registration Number: NCT03783130

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Prevalence and Incidence of Lassa Virus Infection in Southern Mali

Completed

Conditions: Lassa Virus Infection

First Posted Date: 2018-12-20

Last Posted Date: 2025-05-18

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 8524

Registration Number: NCT03783143

Locations: 🇲🇱
Icer/Mrtc/Fmos/Usttb, Bamako, Mali

Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis

Phase 2

Completed

Conditions: Indolent Systemic Mastocytosis

Interventions: Biological: sarilumab
Other: Placebo

First Posted Date: 2018-12-10

Last Posted Date: 2024-12-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 21

Registration Number: NCT03770273

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release)
Drug: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets

First Posted Date: 2018-11-30

Last Posted Date: 2023-06-27

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 57

Registration Number: NCT03760458

Locations: 🇧🇼
Gaborone CRS, Gaborone, Botswana
🇿🇦
Famcru Crs, Tygerberg, Western Cape Province, South Africa
🇹🇭
Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand

and more 11 locations

Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: Oral Cabotegravir (CAB)
Drug: Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Drug: Long-Acting Injectable Cabotegravir (CAB LA)
Biological: VRC07-523LS
Drug: Standard of Care (SOC) ART

First Posted Date: 2018-11-14

Last Posted Date: 2025-05-23

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 75

Registration Number: NCT03739996

Locations: 🇺🇸
Alabama CRS, Birmingham, Alabama, United States
🇺🇸
UCSD Antiviral Research Center CRS, San Diego, California, United States
🇺🇸
Ucsf Hiv/Aids Crs, San Francisco, California, United States

and more 15 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy